A breakout above that area would likely mark the start of a new leg higher, with 175 as a logical upside target.
The relative trend has already broken out. Now it’s the absolute trend’s turn to catch up.
When it comes to exposure in this group, a lot of investors stick with the ETF — and that works. Everyone has different goals, timeframes, and risk tolerance.
For me, I take it a step further and focus on the individual names showing the strongest setups within the sector. That’s where I want to be positioned.
Today, we’re buying a $2.6B biotech through our Minor Leaguers report — a biweekly scan focused on finding the best small-cap opportunities.